81 results about "Substance abuse" patented technology

Pharmaceutical dosage forms are provided for use in deterring abuse of opioids or other medications, which help avoid harm to a patient dependent on the medication. In one case, a pharmaceutical oral dosage form is provided that includes a plurality of microcapsules, each microcapsule of the plurality containing an opioid agonist medication in a controlled release form, and a partial opioid agonist sequestered in the pharmaceutical dosage form, such that upon oral administration of the pharmaceutical oral dosage form the partial opioid agonist will pass through the gastrointestinal tract without uptake by the body.

A system and method for detecting improper drug use utilizes the morphine equivalency of a drug regimen of a patient having an injury to compare the morphine equivalency of the drug regimen of the patient to that of a peer group having the same diagnosis. The comparison may be conducted based on the aggregate morphine equivalency for respective periods of time following the injury or the initial treatment and based on the rate of change in the morphine equivalency for that or another period of time. Based on the results of the comparison, potential instances of drug fraud and / or drug abuse are identified and an alert is generated, and appropriate action is taken, where needed.

The invention discloses a prescription auditing method and a system thereof, wherein the method comprises the steps of extracting medicine taking characteristic information of a patient, and identifying prescription information; according to the medicine taking characteristic information and a pre-trained medicine taking recommending model, obtaining recommending medicine information; and performing rationality auditing on a medicine taking doctor's advice in the prescription information according to the recommending medicine information, the medicine taking characteristic information, a preset expert rule database and a medical body knowledge database. The prescription auditing method and the system thereof have advantages of assisting a prescription pharmacist and a doctor for realizinghigher scientific performance and higher rationality in medicine taking, reducing medical cost of the patient and sanitation resource wastage, realizing in-time finding of the unreasonable medicine taking condition, and maximally alleviating and even settling a medicine abuse problem.

The present invention is directed to the production of PKC isozyme epsi (PKCepsi)-deficient cells and non-human animals. The present invention is further directed to the identification of PKCepsi as a target for drugs that reduce anxiety. According to the present invention, PKCepsi-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKCepsi to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKCepsi, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors. Additional aspects of the present invention are diagnostic methods for identifying individuals at risk for becoming alcoholics or abusers of other drugs and kits for performing such diagnostic methods. The present invention relates to: cells and non-human animals deficient for the PKC isozyme epsi (PKCepsi); the use of PKCepsi as a target for drugs; the use of inhibitors of PKCepsi in methods of reducing anxiety and treating conditions associated with insufficient activity of the GABAA receptor; the use of modulators of PKCepsi in methods of modulating alcohol consumption, modulating self-administration of other drugs of abuse, and altering the effects of alcohol; pharmaceutical compositions comprising inhibitors of PKCepsi and allosteric agonists of GABAA receptors; and the identification of individuals with enhanced susceptibility to alcoholism or other forms of addiction.

A system and method for detecting improper drug use utilizes the morphine equivalency of a drug regimen of a patient having an injury to compare the morphine equivalency of the drug regimen of the patient to that of a peer group having the same diagnosis. The comparison may be conducted based on the aggregate morphine equivalency for respective periods of time following the injury or the initial treatment and based on the rate of change in the morphine equivalency for that or another period of time. Based on the results of the comparison, potential instances of drug fraud and / or drug abuse are identified and an alert is generated, and appropriate action is taken, where needed.

The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on both the 2- and 4-pyridinyl ring having the chemical structure of formula I: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I to modulate GABA and GABAA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and / or GABAA receptors.

The invention relates to new chemical compounds acting on the serotonin transporter (SERT), and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof. In particular the new chemical compounds are useful for the treatment of a variety of central nervous system (CNS) disorders—for example anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, cognitive disorders, sleep disorders, feeding disorders, panic attacks, disorders related to withdrawl from drug abuse, schizophrenia, or the like, or in the treatment of gastrointestinal disorders such as irritable bowel syndrome.

The invention describes the use of an injectable form of Idebenone to induce protect from neuronal damage, improve recovery after brain trauma; stroke, intoxication, neurodegenerative diseases, memory loss or neuropathology associated with neuroinflammation or infection damage and to restore cognitive function, suppress disorientation, alcoholic and drug abuse associated syndromes and other signs of neuronal damage.

The invention provides a sulfocompound with a nerve protection effect from pineapple fruit and preparation and application thereof, belonging to the field of medicine. A sulfur-containing compound with a nerve protection effect is separated from the pineapple fruit through various separation means. The compound has a structural formula (I). Cell experiments indicate that the compound has a better protection effect on nerve cells, and can prevent or treat Parkinson, Alzheimer, Huntington, drug abuse, depression and stroke diseases caused by degeneration or injury of nerve cells resulting from various factors.

Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds, processes for their preparation, medicaments and pharmaceutical compositions containing them, and their use in treatment methods and in the preparation of analgesics, in the preparation of a local anaesthetic, an antiarrhythmic, an antiemetic, a nootropic agent and / or a medicament for the treatment and / or prophylaxis of cardiovascular diseases, urinary incontinence, diarrhea, pruritus and / or inflammations, and / or a medicament for the treatment of depression and / or alcohol and / or drug and / or medicament abuse, and / or a medicament for increasing vigilance.